tradingkey.logo
搜尋

LeonaBio Ord Shs

LONA
添加自選
3.470USD
-0.260-6.97%
收盤 11-13 16:00(美東)
32.69M總市值
虧損本益比TTM

關於 LeonaBio Ord Shs 公司

LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.

LeonaBio Ord Shs 簡介

公司代碼- -
公司名稱- -
上市日期- -
CEO- -
員工數量- -
證券類型- -
年結日- -
公司地址- -
城市- -
上市交易所- -
國家- -
郵編- -
電話- -
網址- -
公司代碼- -
上市日期- -
CEO- -

LeonaBio Ord Shs公司高管

名稱
名稱/職務
職務
持股
持股變動
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Mr. Mark Worthington
Mr. Mark Worthington
Chief Compliance Officer, General Counsel, Company Secretary
Chief Compliance Officer, General Counsel, Company Secretary
18.38K
--
Dr. Javier San Martin, M.D.
Dr. Javier San Martin, M.D.
Chief Medical Officer
Chief Medical Officer
15.89K
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Mark James Litton, Ph.D.
Dr. Mark James Litton, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
59.89K
--
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%
Dr. Kevin Church, Ph.D.
Dr. Kevin Church, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
25.18K
+17.86%

常見問題

LeonaBio Ord Shs的前五大股東是誰?

LeonaBio Ord Shs的前五大股東如下:Dr. Mark James Litton, Ph.D.

有多少機構持有LeonaBio Ord Shs(LONA)的股份?

截至2026Q1,共有120家機構持有LeonaBio Ord Shs的股份,合計持有的股份價值約為6.66M,占公司總股份的70.97% 。與2025Q4相比,機構持股有所增加,增幅為2319889.00。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有